Skip to main content
SpringerLink
Log in
Book cover

Antibody Methods and Protocols pp 11–32Cite as

Recombinant Antibodies and In Vitro Selection Technologies

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 901))

Abstract

Over the past decade, the accumulation of detailed knowledge of antibody structure and function has enabled antibody phage display to emerge as a powerful in vitro alternative to hybridoma methods for creating antibodies. Many antibodies produced using phage display technology have unique properties that are not obtainable using traditional hybridoma technologies. In phage display, selections are performed under controlled, in vitro conditions that are tailored to suit demands of the antigen and the sequence encoding the antibody is immediately available. These features obviate many of the limitations of hybridoma methodology, and because the entire process relies on scalable molecular biology techniques, phage display is also suitable for high-throughput applications. Thus, antibody phage display technology is well suited for genome-scale biotechnology and therapeutic applications. This review describes the antibody phage display technology and highlights examples of antibodies with unique properties that cannot easily be obtained by other technologies.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. von Behring E, Kitasato S (1890) Über das zustandekommen der diphtherie-immunität und der tetanus-immunität bei thieren. Deut Med Wochenzeitschr 16:1113–1114

    Article  Google Scholar 

  2. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497

    Article  PubMed  Google Scholar 

  3. Courtenay-Luck NS, Epenetos AA, Moore R et al (1986) Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 46:6489–6493

    PubMed  CAS  Google Scholar 

  4. Tjandra JJ, Ramadi L, McKenzie IF (1990) Development of human anti-murine antibody (HAMA) response in patients. Immunol Cell Biol 68:367–376

    Article  PubMed  Google Scholar 

  5. Almagro JC, Fransson J (2008) Humanization of antibodies. Front Biosci 13:1619–1633

    PubMed  CAS  Google Scholar 

  6. Hwang WYK, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3–10

    Article  PubMed  CAS  Google Scholar 

  7. Kashmiri SVS, De Pascalis R, Gonzales NR, Schlom J (2005) SDR grafting—a new approach to antibody humanization. Methods 36:25–34

    Article  PubMed  CAS  Google Scholar 

  8. Studnicka GM, Soares S, Better M et al (1994) Human engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng 7:805–814

    Article  PubMed  CAS  Google Scholar 

  9. Osbourn J, Groves M, Vaughan T (2005) From rodent reagents to human therapeutics using antibody guided selection. Methods 36: 61–68

    Article  PubMed  CAS  Google Scholar 

  10. Fishwild DM, O’Donnell SL, Bengoechea T et al (1996) High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 14:845–851

    Article  PubMed  CAS  Google Scholar 

  11. Jakobovits A (1995) Production of fully human antibodies by transgenic mice. Curr Opin Biotechnol 6:561–566

    Article  PubMed  CAS  Google Scholar 

  12. Kuroiwa Y, Kasinathan P, Sathiyaseelan T et al (2009) Antigen specific human polyclonal antibodies from hyperimmunized cattle. Nat Biotechnol 27:173–181

    Article  PubMed  CAS  Google Scholar 

  13. Lonberg N, Huszar D (1995) Human antibodies from transgenic mice. Int Rev Immunol 13:65–93

    Article  PubMed  CAS  Google Scholar 

  14. Weiner LM (2006) Fully human therapeutic monoclonal antibodies. J Immunother 29:1–9

    Article  PubMed  CAS  Google Scholar 

  15. Winter G, Milstein C (1991) Man-made antibodies. Nature 349:293–299

    Article  PubMed  CAS  Google Scholar 

  16. McCafferty J, Griffiths AD, Winter G et al (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552–554

    Article  PubMed  CAS  Google Scholar 

  17. Marks JD, Hoogenboom HR, Bonnert TP et al (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Bio 222:581–597

    Article  CAS  Google Scholar 

  18. Breitling F, Dübel S, Seehaus T (1991) A surface expression vector for antibody screening. Gene 104:147–153

    Article  PubMed  CAS  Google Scholar 

  19. Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553–557

    Article  PubMed  CAS  Google Scholar 

  20. Feldhaus MJ, Siegel RW, Opresko LK et al (2003) Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol 21:163–170

    Article  PubMed  CAS  Google Scholar 

  21. He M, Taussig MJ (2007) Rapid discovery of protein interactions by cell-free protein technologies. Biochem Soc Trans 35:962–965

    Article  PubMed  CAS  Google Scholar 

  22. Jostock T, Dübel S (2005) Screening of molecular repertoires by microbial surface display. Comb Chem High Throughput Screen 8:127–133

    Article  PubMed  CAS  Google Scholar 

  23. Paschke M (2006) Phage display systems and their applications. Appl Microbiol Biotechnol 70:2–11

    Article  PubMed  CAS  Google Scholar 

  24. Zahnd C, Amstutz P, Pluckthun A (2007) Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods 4:269–279

    Article  PubMed  CAS  Google Scholar 

  25. Chao G, Lau WL, Hackel BJ et al (2006) Isolating and engineering human antibodies using yeast surface display. Nat Protoc 1: 755–768

    Article  PubMed  CAS  Google Scholar 

  26. Benhar I (2007) Design of synthetic antibody libraries. Expert Opin Biol Ther 7:763–779

    Article  PubMed  CAS  Google Scholar 

  27. Bradbury AR, Marks JD (2004) Antibodies from phage antibody libraries. J Immunol Methods 290:29–49

    Article  PubMed  CAS  Google Scholar 

  28. Dübel S, Stoevesandt O, Taussig MJ et al (2010) Generating recombinant antibodies to the complete human proteome. Trends Biotechnol 28:333–339

    Article  PubMed  CAS  Google Scholar 

  29. Mersmann M, Meier D, Mersmann J et al (2010) Towards proteome scale antibody selections using phage display. New Biotechnol 27:118–128

    Article  CAS  Google Scholar 

  30. Schofield DJ et al (2007) Application of phage display to high throughput antibody generation and characterization. Genome Biol 8:R254

    Article  PubMed  CAS  Google Scholar 

  31. Colwill K, Gräslund S, Persson MA et al (2011) A roadmap to generate renewable protein binders to the human proteome. Nat Methods 8:551–561

    Article  PubMed  CAS  Google Scholar 

  32. Hust M, Meyer T, Voedisch B et al (2011) A human scFv antibody generation pipeline for proteome research. J Biotechnol 152: 159–170

    Article  PubMed  CAS  Google Scholar 

  33. Koide A, Bailey CW, Huang X et al (1998) The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 284: 1141–1151

    Article  PubMed  CAS  Google Scholar 

  34. Angenendt P, Wilde J, Kijanka G et al (2004) Seeing better through a MIST: evaluation of monoclonal recombinant antibody fragments on microarrays. Anal Chem 76:2916–2921

    Article  PubMed  CAS  Google Scholar 

  35. Philibert P, Stoessel A, Wang W (2007) A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm. BMC Biotechnol 7:1472–6750

    Article  CAS  Google Scholar 

  36. Parsons HL, Earnshaw JC, Wilton J et al (1996) Directing phage selections towards specific epitopes. Protein Eng 9:1043–1049

    Article  PubMed  CAS  Google Scholar 

  37. Lassen KS, Bradbury AR, Rehfeld JF et al (2008) Microscale characterization of the binding specificity and affinity of a monoclonal antisulfotyrosyl IgG antibody. Electrophoresis 29:2557–2564

    Article  PubMed  CAS  Google Scholar 

  38. Kehoe JW, Velappan N, Walbol M et al (2006) Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics 5:2350–2363

    Article  PubMed  CAS  Google Scholar 

  39. Hoffhines AJ, Damoc E, Bridges KG et al (2006) Detection and purification of tyrosine-sulfated proteins using a novel anti-sulfotyrosine monoclonal antibody. J Biol Chem 281:37877–37887

    Article  PubMed  CAS  Google Scholar 

  40. Raza A, Garcia-Rodriguez C, Lou J et al (2005) Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 351:158–169

    Article  CAS  Google Scholar 

  41. Lee CV, Liang WC, Dennis MS et al (2004) High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 340: 1073–1093

    Article  PubMed  CAS  Google Scholar 

  42. Hanes J, Schaffitzel C, Knappik A et al (2000) Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat Biotechnol 18: 1287–1292

    Article  PubMed  CAS  Google Scholar 

  43. Schier R, McCall A, Adams GP et al (1996) Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 263:551–567

    Article  PubMed  CAS  Google Scholar 

  44. Yang WP, Green K, Pinz-Sweeney S et al (1995) CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 254:392–403

    Article  PubMed  CAS  Google Scholar 

  45. Boder ET, Midelfort KS, Wittrup KD (2000) Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci USA 97:10701–10705

    Article  PubMed  CAS  Google Scholar 

  46. Foote J, Eisen HN (1995) Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci USA 92: 1254–1256

    Article  PubMed  CAS  Google Scholar 

  47. Foote J, Eisen HN (2000) Breaking the affinity ceiling for antibodies and T cell receptors. Proc Natl Acad Sci USA 97:10679–10681

    Article  PubMed  CAS  Google Scholar 

  48. Batista FD, Neuberger MS (1998) Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 8:751–759

    Article  PubMed  CAS  Google Scholar 

  49. Sidhu SS (2005) Phage display in biotechnology and drug discovery. CRC Press, Baco Raton, FL

    Book  Google Scholar 

  50. Ponsel D, Neugebauer J, Ladetzki-Baehs K et al (2011) High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. Molecules 16:3675–3700

    Article  PubMed  CAS  Google Scholar 

  51. Azzazy HM, Highsmith WE Jr (2002) Phage display technology: clinical applications and recent innovations. Clin Biochem 35: 425–445

    Article  PubMed  CAS  Google Scholar 

  52. Benhar I (2007) Design of synthetic antibody libraries. Expert Opin Biol Ther 7:763–779

    Article  PubMed  CAS  Google Scholar 

  53. Burton DR, Barbas CF III, Persson MA et al (1991) A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 88:10134–10137

    Article  PubMed  CAS  Google Scholar 

  54. Kramer RA, Marissen WE, Goudsmit J et al (2005) The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol 35:2131–2145

    Article  PubMed  CAS  Google Scholar 

  55. de Carvalho NC, Williamson RA, Parren PW et al (2002) Neutralizing human Fab fragments against measles virus recovered by phage display. J Virol 76:251–258

    Article  Google Scholar 

  56. Zebedee SL, Barbas CF III, Hom YL et al (1992) Human combinatorial antibody libraries to hepatitis B surface antigen. Proc Natl Acad Sci USA 89:3175–3179

    Article  PubMed  CAS  Google Scholar 

  57. Cai X, Garen A (1995) Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci USA 92:6537–6541

    Article  PubMed  CAS  Google Scholar 

  58. Vaughan TJ, Williams AJ, Pritchard K et al (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14:309–314

    Article  PubMed  CAS  Google Scholar 

  59. Lloyd C, Lowe D, Edwards B et al (2009) Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel 22: 159–168

    Article  PubMed  CAS  Google Scholar 

  60. Sheets MD, Amersdorfer P, Finnern R et al (1998) Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci USA 95:6157–6162

    Article  PubMed  CAS  Google Scholar 

  61. De Haard HJ (2002) Construction of large naive Fab libraries. Methods Mol Biol 178: 87–100

    PubMed  Google Scholar 

  62. Nissim A, Hoogenboom HR, Tomlinson IM et al (1994) Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents. EMBO J 13:692–698

    PubMed  CAS  Google Scholar 

  63. de Kruif J, Boel E, Logtenberg T (1995) Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J Mol Biol 248: 97–105

    Article  PubMed  CAS  Google Scholar 

  64. Griffiths AD, Williams SC, Hartley O et al (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 13:3245–3260

    PubMed  CAS  Google Scholar 

  65. Hoogenboom HR, Winter G (1992) By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol 227:381–388

    Article  PubMed  CAS  Google Scholar 

  66. Pini A, Viti F, Santucci A et al (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 273: 21769–21776

    Article  PubMed  CAS  Google Scholar 

  67. Hoet RM, Cohen EH, Kent RB et al (2005) Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol 23:344–348

    Article  PubMed  CAS  Google Scholar 

  68. Lee CV, Liang WC, Dennis MS et al (2004) High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 340: 1073–1093

    Article  PubMed  CAS  Google Scholar 

  69. Söderlind E, Strandberg L, Jirholt P et al (2000) Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 18:852–856

    Article  PubMed  Google Scholar 

  70. Rothe C, Urlinger S, Lohning C et al (2008) The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 376:1182–1200

    Article  PubMed  CAS  Google Scholar 

  71. Sidhu SS, Li B, Chen Y, Fellouse FA et al (2004) Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol 338:299–310

    Article  PubMed  CAS  Google Scholar 

  72. Fellouse FA, Wiesmann C, Sidhu SS (2004) Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci USA 101:12467–12472

    Article  PubMed  CAS  Google Scholar 

  73. Fellouse FA, Li B, Compaan DM, Peden AA et al (2005) Molecular recognition by a binary code. J Mol Biol 348:1153–1162

    Article  PubMed  CAS  Google Scholar 

  74. Russel M, Linderoth NA, Sali A (1997) Filamentous phage assembly: variation on a protein export theme. Gene 192:23–32

    Article  PubMed  CAS  Google Scholar 

  75. Iannolo G, Minenkova O, Petruzzelli R et al (1995) Modifying filamentous phage capsid: limits in the size of the major capsid protein. J Mol Biol 248:835–844

    Article  PubMed  CAS  Google Scholar 

  76. Kretzschmarm T, Geiser M (1995) Evaluation of antibodies fused to minor coat protein III and major coat protein VIII of bacteriophage M13. Gene 155:61–65

    Article  Google Scholar 

  77. Rondot S, Koch J, Breitling F et al (2001) A helper phage to improve single chain antibody presentation in phage display. Nat Biotechnol 19:75–78

    Article  PubMed  CAS  Google Scholar 

  78. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767–774

    Article  PubMed  CAS  Google Scholar 

  79. Edwards BM, Barash SC, Main SH et al (2003) The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol 334:103–118

    Article  PubMed  CAS  Google Scholar 

  80. Baker KP, Edwards BM, Main SH et al (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48:3253–3265

    Article  PubMed  CAS  Google Scholar 

  81. Lloyd C, Lowe D, Edwards B et al (2009) Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel 22:159–168

    Article  PubMed  CAS  Google Scholar 

  82. Dong J, Demarest SJ, Sereno A et al (2010) Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 9:2593–2604

    Article  PubMed  CAS  Google Scholar 

  83. Doern A, Cao X, Sereno A et al (2009) Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo. J Biol Chem 284:10254–10267

    Article  PubMed  CAS  Google Scholar 

  84. Dong J, Sereno A, Snyder WB et al (2011) Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 286:4703–4717

    Article  PubMed  CAS  Google Scholar 

  85. Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138–1144

    Article  PubMed  CAS  Google Scholar 

  86. Wu Y, Cain-Hom C, Choy L et al (2010) Therapeutic antibody targeting of individual Notch receptors. Nature 464:1052–1057

    Article  PubMed  CAS  Google Scholar 

  87. Xie MH, Yuan J, Adams C et al (1997) Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv. Nat Biotechnol 15:768–771

    Article  PubMed  CAS  Google Scholar 

  88. Ellmark P, Andersson H, Abayneh S et al (2008) Identification of a strongly activating human anti-CD40 antibody that suppresses HIV type 1 infection. AIDS Res Hum Retroviruses 24:367–373

    Article  PubMed  CAS  Google Scholar 

  89. Dobson CL, Main S, Newton P et al (2009) Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism. MAbs 1:552–562

    Article  PubMed  Google Scholar 

  90. Eisenhardt SU, Schwarz M, Bassler N et al (2007) Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules. Nat Protoc 2:3063–3073

    Article  PubMed  CAS  Google Scholar 

  91. Huie MA, Cheung MC, Muench MO et al (2001) Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc Natl Acad Sci USA 98:2682–2687

    Article  PubMed  CAS  Google Scholar 

  92. Noronha EJ, Wang X, Desai SA et al (1998) Limited diversity of human scFv fragments isolated by panning a synthetic phage-display scFv library with cultured human melanoma cells. J Immunol 161:2968–2976

    PubMed  CAS  Google Scholar 

  93. Ridgway JB, Ng E, Kern JA et al (1999) Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines. Cancer Res 59:2718–2723

    PubMed  CAS  Google Scholar 

  94. Van Ewijk W, de Kruif J, Germeraad WT et al (1997) Subtractive isolation of phage-displayed single-chain antibodies to thymic stromal cells by using intact thymic fragments. Proc Natl Acad Sci USA 94:3903–3908

    Article  PubMed  Google Scholar 

  95. Giordano RJ, Cardo-Vila M, Lahdenranta J et al (2001) Biopanning and rapid analysis of selective interactive ligands. Nat Med 7:1249–1253

    Article  PubMed  CAS  Google Scholar 

  96. Williams BR, Sharon J (2002) Polyclonal anti-colorectal cancer Fab phage display library selected in one round using density gradient centrifugation to separate antigen-bound and free phage. Immunol Lett 81:141–148

    Article  PubMed  CAS  Google Scholar 

  97. Osbourn JK, Derbyshire EJ, Vaughan TJ et al (1998) Pathfinder selection: in situ isolation of novel antibodies. Immunotechnology 3:293–302

    Article  PubMed  CAS  Google Scholar 

  98. Osbourn JK, Earnshaw JC, Johnson KS et al (1998) Directed selection of MIP-1 alpha neutralizing CCR5 antibodies from a phage display human antibody library. Nat Biotechnol 16:778–781

    Article  PubMed  CAS  Google Scholar 

  99. Poul MA, Becerril B, Nielsen UB et al (2000) Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol 301:1149–1161

    Article  PubMed  CAS  Google Scholar 

  100. Zhou Y, Marks JD (2009) Identification of target and function specific antibodies for effective drug delivery. Methods Mol Biol 525:145–160

    Article  PubMed  CAS  Google Scholar 

  101. Crépin R, Goenaga AL, Jullienne B et al (2010) Development of human single-chain antibodies to the transferrin receptor t, hat effectively antagonize the growth of leukemias and lymphomas. Cancer Res 70:5497–5506

    Article  PubMed  CAS  Google Scholar 

  102. Park JW, Kirpotin DB, Hong K et al (2001) Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95–113

    Article  PubMed  CAS  Google Scholar 

  103. Nielsen UB, Kirpotin DB, Pickering EM et al (2002) Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 1591:109–118

    Article  PubMed  CAS  Google Scholar 

  104. Velappan N, Martinez JS, Valero R et al (2007) Selection and characterization of scFv antibodies against the Sin Nombre hantavirus nucleocapsid protein. J Immunol Methods 321:60–69

    Article  PubMed  CAS  Google Scholar 

  105. Cabezas S, Rojas G, Pavon A et al (2009) Phage-displayed antibody fragments recognizing dengue 3 and dengue 4 viruses as tools for viral serotyping in sera from infected individuals. Arch Virol 154:1035–1045

    Article  PubMed  CAS  Google Scholar 

  106. Cabezas S, Rojas G, Pavon A et al (2008) Selection of phage-displayed human antibody fragments on Dengue virus particles captured by a monoclonal antibody: application to the four serotypes. J Virol Methods 147:235–243

    Article  PubMed  CAS  Google Scholar 

  107. Lim AP, Chan CE, Wong SK et al (2008) Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library. Virol J 5:130

    Article  PubMed  CAS  Google Scholar 

  108. Okada J, Ohshima N, Kubota-Koketsu R et al (2010) Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified into three groups with distinct strain specificity: 1968–1973, 1977–1993 and 1997–2003. Virology 397:322–330

    Article  PubMed  CAS  Google Scholar 

  109. Meissner F, Maruyama T, Frentsch M et al (2002) Detection of antibodies against the four subtypes of ebola virus in sera from any species using a novel antibody-phage indicator assay. Virology 300:236–243

    Article  PubMed  CAS  Google Scholar 

  110. Kirsch MI, Hülseweh B, Nacke C et al (2008) Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol 8:66

    Article  PubMed  CAS  Google Scholar 

  111. Hayhurst A, Happe S, Mabry R et al (2003) Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis. J Immunol Methods 276:185–196

    Article  PubMed  CAS  Google Scholar 

  112. Zou N, Newsome T, Li B et al (2007) Human single-chain Fv antibodies against Burkholderia mallei and Burkholderia pseudomallei. Exp Biol Med (Maywood) 232:550–556

    CAS  Google Scholar 

  113. Maynard JA, Maassen CB, Leppla SH et al (2002) Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 20:597–601

    Article  PubMed  CAS  Google Scholar 

  114. Wild MA, Xin H, Maruyama T et al (2003) Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat Biotechnol 21:1305–1306

    Article  PubMed  CAS  Google Scholar 

  115. Steiniger SC, Altobell LJ 3rd, Zhou B, Janda KD (2007) Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen. Mol Immunol 44:2749–2755

    Article  PubMed  CAS  Google Scholar 

  116. Pelat T, Hust M, Laffly E et al (2007) ­High-affinity, human antibody-like antibody ­fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 51:2758–2764

    Article  PubMed  CAS  Google Scholar 

  117. Cirino NM, Sblattero D, Allen D et al (1999) Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect Immun 67:2957–2963

    PubMed  CAS  Google Scholar 

  118. Zhou B, Wirsching P, Janda KD (2002) Human antibodies against spores of the genus Bacillus: a model study for detection of and protection against anthrax and the bioterrorist threat. Proc Natl Acad Sci USA 99:5241–5246

    Article  PubMed  CAS  Google Scholar 

  119. Sui J, Hwang WC, Perez S et al (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265–273

    Article  PubMed  CAS  Google Scholar 

  120. Sun L, Lu X, Li C et al (2009) Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 4:e5476

    Article  PubMed  CAS  Google Scholar 

  121. Throsby M, van den Brink E, Jongeneelen M et al (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM  +  memory B cells. PLoS One 3:e3942

    Article  PubMed  CAS  Google Scholar 

  122. Ayriss J, Woods T, Bradbury A, Pavlik P (2007) High-throughput screening of single-chain antibodies using multiplexed flow cytometry. J Proteome Res 6:1072–1082

    Article  PubMed  CAS  Google Scholar 

  123. Pershad K, Pavlovic JD, Gräslund S et al (2010) Generating a panel of highly specific antibodies to 20 human SH2 domains by phage display. Protein Eng Des Sel 23:279–288

    Article  PubMed  CAS  Google Scholar 

  124. Parsons HL, Earnshaw JC, Wilton J et al (1996) Directing phage selections towards specific epitopes. Protein Eng 9:1043–1049

    Article  PubMed  CAS  Google Scholar 

  125. Mutuberria R, Satijn S, Huijbers A et al (2004) Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries. J Immunol Methods 287:31–47

    Article  PubMed  CAS  Google Scholar 

  126. Cohen CJ, Denkberg G, Lev A et al (2003) Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J Mol Recognit 16:324–332

    Article  PubMed  CAS  Google Scholar 

  127. Engberg J, Krogsgaard M, Fugger L (1999) Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: novel reagents for basic and clinical investigations and immunotherapy. Immunotechnology 4:273–278

    Article  PubMed  CAS  Google Scholar 

  128. Stryhn A, Andersen PS, Pedersen LO et al (1996) Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex. Proc Natl Acad Sci USA 93:10338–10342

    Article  PubMed  CAS  Google Scholar 

  129. Villa A, Trachsel E, Kaspar M et al (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122:2405–2413

    Article  PubMed  CAS  Google Scholar 

  130. Pini A, Viti F, Santucci A et al (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 273:21769–21776

    Article  PubMed  CAS  Google Scholar 

  131. Schliemann C, Neri D (2010) Antibody-based vascular tumor targeting. Recent Results Cancer Res 180:201–216

    Article  PubMed  CAS  Google Scholar 

  132. Nizak C, Monier S, del Nery E et al (2003) Recombinant antibodies to the small GTPase Rab6 as conformation sensors. Science 300:984–987

    Article  PubMed  CAS  Google Scholar 

  133. Gao J, Sidhu SS, Wells JA (2009) Two-state selection of conformation-specific antibodies. Proc Natl Acad Sci USA 106:3071–3076

    Article  PubMed  CAS  Google Scholar 

  134. Eisenhardt SU, Schwarz M, Bassler N, Peter K (2007) Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules. Nat Protoc 2:3063–3073

    Article  PubMed  CAS  Google Scholar 

  135. Rothlisberger D, Pos KM, Pluckthun A (2004) An antibody library for stabilizing and crystallizing membrane proteins - selecting binders to the citrate carrier CitS. FEBS Lett 564:340–348

    Article  PubMed  CAS  Google Scholar 

  136. Uysal S, Vásquez V, Tereshko V et al (2009) Crystal structure of full-length KcsA in its closed conformation. Proc Natl Acad Sci USA 106:6644–6649

    Article  PubMed  CAS  Google Scholar 

  137. Ye JD, Tereshko V, Frederiksen JK et al (2008) Synthetic antibodies for specific recognition and crystallization of structured RNA. Proc Natl Acad Sci USA 105:82–87

    Article  PubMed  CAS  Google Scholar 

  138. Koldobskaya Y, Duguid EM, Shechner DM et al (2010) A portable RNA sequence whose recognition by a synthetic antibody facilitates structural determination. Nat Struct Mol Biol 18:100–106

    Article  PubMed  CAS  Google Scholar 

  139. Monigatti F, Gasteiger E, Bairoch A, Jung E (2002) The Sulfinator: predicting tyrosine sulfation sites in protein sequences. Bioinformatics 18:769–770

    Article  PubMed  CAS  Google Scholar 

  140. Kehoe JW, Velappan N, Walbolt M et al (2006) Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics 5:2350–2363

    Article  PubMed  CAS  Google Scholar 

  141. Thie H, Voedisch B, Dübel S et al (2009) Affinity maturation by phage display. Methods Mol Biol 525:309–322

    Article  PubMed  CAS  Google Scholar 

  142. Cadwell RC, Joyce GF (1994) Mutagenic PCR. PCR Methods Appl 3:S136–S140

    PubMed  CAS  Google Scholar 

  143. Stemmer WP (1994) DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. Proc Natl Acad Sci USA 91:10747–10751

    Article  PubMed  CAS  Google Scholar 

  144. Fellouse FA, Wiesmann C, Sidhu SS (2004) Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci USA 101:12467–12472

    Article  PubMed  CAS  Google Scholar 

  145. Liang WC, Wu X, Peale FV et al (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281:951–961

    Article  PubMed  CAS  Google Scholar 

  146. Lee CV, Hymowitz SG, Wallweber HJ et al (2006) Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood 108:3103–3111

    Article  PubMed  CAS  Google Scholar 

  147. Fagète S, Ravn U, Gueneau F et al (2009) Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent. MAbs 1:288–296

    Article  PubMed  Google Scholar 

  148. Bostrom J, Yu SF, Kan D et al (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323:1610–1614

    Article  PubMed  CAS  Google Scholar 

  149. Volk WA, Bizzini B, Snyder RM et al (1984) Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun 45:604–609

    PubMed  CAS  Google Scholar 

  150. Zwick MB, Labrijn AF, Wang M et al (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75:10892–10905

    Article  PubMed  CAS  Google Scholar 

  151. Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Eng J Med 359:613–626

    Article  CAS  Google Scholar 

  152. de Kruif J, Logtenberg T (1996) Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J Biol Chem 271: 7630–7634

    Article  PubMed  Google Scholar 

  153. Thie H, Binius S, Schirrmann T et al (2009) Multimerization domains for antibody phage display and antibody production. New Biotechnol 26:314–321

    Article  CAS  Google Scholar 

  154. Hudson PJ, Kortt AA (1999) High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 231:177–189

    Article  PubMed  CAS  Google Scholar 

  155. Dübel S, Breitling F, Kontermann R et al (1995) Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). J Immunol Methods 178:201–209

    Article  PubMed  Google Scholar 

  156. Huang D, Shusta EV (2006) A yeast platform for the production of single-chain antibody-green fluorescent protein fusions. Appl Environ Microbiol 72:7748–7759

    Article  PubMed  CAS  Google Scholar 

  157. Hink MA, Griep RA, Borst JW et al (2000) Structural dynamics of green fluorescent protein alone and fused with a single chain Fv protein. J Biol Chem 275:17556–17560

    Article  PubMed  CAS  Google Scholar 

  158. Casey JL, Coley AM, Tilley LM et al (2000) Green fluorescent antibodies: novel in vitro tools. Protein Eng 13:445–452

    Article  PubMed  CAS  Google Scholar 

  159. Griep RA, van Twisk C, Kerschbaumer RJ et al (1999) pSKAP/S: an expression vector for the production of single-chain Fv alkaline phosphatase fusion proteins. Protein Expr Purif 16:63–69

    Article  PubMed  CAS  Google Scholar 

  160. Al-Mrabeh A, Ziegler A, Cowan G et al (2009) A fully recombinant ELISA using in vivo biotinyla.ted antibody fragments for the detection of potato leafroll virus. J Virol Methods 159:200–205

    Article  PubMed  CAS  Google Scholar 

  161. Predonzani A, Arnoldi F, Lopez-Requena A et al (2008) In vivo site-specific biotinylation of proteins within the secretory pathway using a single vector system. BMC Biotechnol 8:41

    Article  PubMed  CAS  Google Scholar 

  162. Warren DJ, Bjerner J, Paus E et al (2005) Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. Clin Chem 51: 830–838

    Article  PubMed  CAS  Google Scholar 

  163. Cloutier SM, Couty S, Terskikh A et al (2000) Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin. Mol Immunol 37:1067–1077

    Article  PubMed  CAS  Google Scholar 

  164. Moutel S et al (2009) A multi-Fc-species system for recombinant antibody production. BMC Biotechnol 9:14

    Article  PubMed  CAS  Google Scholar 

  165. Hu S, Shively L, Raubitschek A et al (1996) Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56:3055–3061

    PubMed  CAS  Google Scholar 

  166. Gilliland LK, Norris NA, Marquardt H et al (1996) Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments. Tissue Antigens 47:1–20

    Article  PubMed  CAS  Google Scholar 

  167. Shan D, Press OW, Tsu TT et al (1999) Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J Immunol 162:6589–6595

    PubMed  CAS  Google Scholar 

  168. Kontermann RE (2010) Alternative antibody formats. Curr Opin Mol Ther 12:176–183

    PubMed  CAS  Google Scholar 

  169. Merchant AM, Zhu Z, Yuan JQ et al (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16:677–681

    Article  PubMed  CAS  Google Scholar 

  170. Ridgway JB, Presta LG et al (1996) ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9:617–621

    Article  PubMed  CAS  Google Scholar 

  171. Coloma MJ, Morrison SL (1997) Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15:159–163

    Article  PubMed  CAS  Google Scholar 

  172. Dong J, Sereno A, Snyder WB et al (2011) Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 286:4703–4717

    Article  PubMed  CAS  Google Scholar 

  173. Kortt AA, Dolezal O, Power BE et al (2001) Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 18: 95–108

    Article  PubMed  CAS  Google Scholar 

  174. Lawrence LJ, Kortt AA, Iliades P et al (1998) Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments. FEBS Lett 425:479–484

    Article  PubMed  CAS  Google Scholar 

  175. Perisic O, Webb PA, Holliger P et al (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2:1217–1226

    Article  PubMed  CAS  Google Scholar 

  176. Atwell JL, Breheney KA, Lawrence LJ et al (1999) scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng 12: 597–604

    Article  PubMed  CAS  Google Scholar 

  177. Pei XY, Holliger P, Murzin AG et al (1997) The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. Proc Natl Acad Sci USA 94:9637–9642

    Article  PubMed  CAS  Google Scholar 

  178. Le Gall F, Kipriyanov SM, Moldenhauer G et al (1999) Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett 453:164–168

    Article  PubMed  Google Scholar 

  179. Muller D, Kontermann RE (2010) Bispecific antibodies for cancer immunotherapy: current perspectives. BioDrugs 24:89–98

    Article  PubMed  Google Scholar 

  180. Beck A, Wagner-Rousset E, Bussat MC et al (2008) Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 9:482–501

    Article  PubMed  CAS  Google Scholar 

  181. Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20:460–470

    Article  PubMed  CAS  Google Scholar 

  182. Hallborn J, Carlsson R (2002) Automated screening procedure for high-throughput generation of antibody fragments. Biotechniques Suppl, 30–37

    Google Scholar 

  183. Lou J, Marzari R, Verzillo V et al (2001) Antibodies in haystacks: how selection strategy influences the outcome of selection from molecular diversity libraries. J Immunol Methods 253:233–242

    Article  PubMed  CAS  Google Scholar 

  184. Kawe M, Forrer P, Amstutz P et al (2006) Isolation of intracellular proteinase inhibitors derived from designed ankyrin repeat proteins by genetic screening. J Biol Chem 281: 40252–40263

    Article  PubMed  CAS  Google Scholar 

  185. Glanville J, Zhai W, Berka J et al (2009) Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci USA 106:20216–20221

    Article  PubMed  CAS  Google Scholar 

  186. Ravn U, Gueneau F, Baerlocher L et al (2010) By-passing in vitro screening-next generation sequencing technologies applied to antibody display and in silico candidate selection. Nucleic Acids Res 38:e193

    Article  PubMed  CAS  Google Scholar 

  187. Ge X, Mazor Y, Hunicke-Smith SP et al (2010) Rapid construction and characterization of synthetic antibody libraries without DNA amplification. Biotechnol Bioeng 106: 347–357

    PubMed  CAS  Google Scholar 

  188. Fischer N (2011) Sequencing antibody repertoires: the next generation. MAbs 3: 17–20

    Article  PubMed  Google Scholar 

  189. Reddy ST, Ge X, Miklos AE et al (2010) Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat Biotechnol 28: 965–969

    Article  PubMed  CAS  Google Scholar 

  190. Zhang H, Torkamani A, Jones TM et al (2011) Phenotype-information-phenotype cycle for deconvolution of combinatorial antibody libraries selected against complex systems. Proc Natl Acad Sci USA 108: 13456–13461

    Article  PubMed  CAS  Google Scholar 

  191. Bordeaux J, Welsh A, Agarwal S et al (2010) Antibody validation. Biotechniques 48: 197–209

    Article  PubMed  CAS  Google Scholar 

  192. Pozner-Moulis S, Cregger M, Camp RL et al (2007) Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest 87:251–260

    Article  PubMed  CAS  Google Scholar 

  193. Grimsey NL, Goodfellow CE, Scotter EL et al (2008) Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! J Neurosci Methods 171:78–86

    Article  PubMed  CAS  Google Scholar 

  194. Saper CB (2005) An open letter to our readers on the use of antibodies. J Comp Neurol 493:477–478

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Saskatchewan, Saskatoon, SK, Canada

    C. Ronald Geyer

  2. University of Cambridge, Cambridge, UK

    John McCafferty

  3. Technische Universität Braunschweig, Braunschweig, Germany

    Stefan Dübel

  4. Los Alamos National Laboratory, Los Alamos, NM, USA

    Andrew R. M. Bradbury

  5. University of Toronto, Toronto, ON, Canada

    Sachdev S. Sidhu

Authors
  1. C. Ronald Geyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John McCafferty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Dübel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew R. M. Bradbury
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sachdev S. Sidhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Ronald Geyer .

Editor information

Editors and Affiliations

  1. The Jackson Laboratory, Main Street 600, Bar Harbor, 04609, Maine, USA

    Gabriele Proetzel

  2. Novartis Pharma AG, Postfach, Basel, 4002, Switzerland

    Hilmar Ebersbach

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Geyer, C.R., McCafferty, J., Dübel, S., Bradbury, A.R.M., Sidhu, S.S. (2012). Recombinant Antibodies and In Vitro Selection Technologies. In: Proetzel, G., Ebersbach, H. (eds) Antibody Methods and Protocols. Methods in Molecular Biology, vol 901. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-931-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-931-0_2

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-930-3

  • Online ISBN: 978-1-61779-931-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation